Delayed diagnosis and treatment of children with cancer during the COVID-19 pandemic.

COVID-19 Delayed diagnosis Delayed treatment Pediatric cancer

Journal

International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 09 01 2021
accepted: 28 04 2021
pubmed: 20 6 2021
medline: 20 6 2021
entrez: 19 6 2021
Statut: ppublish

Résumé

COVID-19, the novel coronavirus has caused a global pandemic affecting millions of people around the world. Although children, including children with cancer, have been found to be affected less commonly and less severely than adults, indirect effects of the pandemic on the diagnosis and treatment of children with cancer have been less described. A survey was performed in the four largest tertiary pediatric hematology-oncology medical centers in Israel. Clinical and laboratory data were collected from the medical files of patients diagnosed or treated with cancer during April-October 2020. Seventeen patients are described, who had a significant delay in diagnosis or treatment of cancer. These represent approximately 10% of all pediatric cancer diagnosed during the study period in these centers. A main cause of delay was fear of exposure to COVID-19 (fears felt by the patient, parent, physician, or decision-makers at the institution; or the implementation of national guidelines). Delays also resulted from co-infection with COVID-19 and the attribution of the oncologic symptoms to the infection. In addition, treatment was delayed of patients already diagnosed with cancer, due to COVID-19 infection detected in the patient, a family member, or a bone marrow donor. Fear from the COVID-19 pandemic may result in delayed diagnosis and treatment of children with cancer, which may carry a risk to dismal prognosis. It is crucial that pediatricians and patients alike remember that other diseases still prevail and must be thought of and treated in a timely fashion.

Sections du résumé

BACKGROUND BACKGROUND
COVID-19, the novel coronavirus has caused a global pandemic affecting millions of people around the world. Although children, including children with cancer, have been found to be affected less commonly and less severely than adults, indirect effects of the pandemic on the diagnosis and treatment of children with cancer have been less described.
METHODS METHODS
A survey was performed in the four largest tertiary pediatric hematology-oncology medical centers in Israel. Clinical and laboratory data were collected from the medical files of patients diagnosed or treated with cancer during April-October 2020.
RESULTS RESULTS
Seventeen patients are described, who had a significant delay in diagnosis or treatment of cancer. These represent approximately 10% of all pediatric cancer diagnosed during the study period in these centers. A main cause of delay was fear of exposure to COVID-19 (fears felt by the patient, parent, physician, or decision-makers at the institution; or the implementation of national guidelines). Delays also resulted from co-infection with COVID-19 and the attribution of the oncologic symptoms to the infection. In addition, treatment was delayed of patients already diagnosed with cancer, due to COVID-19 infection detected in the patient, a family member, or a bone marrow donor.
CONCLUSION CONCLUSIONS
Fear from the COVID-19 pandemic may result in delayed diagnosis and treatment of children with cancer, which may carry a risk to dismal prognosis. It is crucial that pediatricians and patients alike remember that other diseases still prevail and must be thought of and treated in a timely fashion.

Identifiants

pubmed: 34145514
doi: 10.1007/s10147-021-01971-3
pii: 10.1007/s10147-021-01971-3
pmc: PMC8212900
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1569-1574

Informations de copyright

© 2021. Japan Society of Clinical Oncology.

Références

World Health Organization (WHO) Coronavirus Disease (COVID-19) dashboard. https://covid19.who.int . Accessed 26 Oct 2020
Posfay-Barbe KM, Wagner N et al (2020) COVID-19 in children and the dynamics of infection in families. Pediatrics 146(2):e20201576. https://doi.org/10.1542/peds.2020-1576
doi: 10.1542/peds.2020-1576 pubmed: 32457213
Docherty AB, Harrison EM et al (2020) Features of 20133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 369:m1985
doi: 10.1136/bmj.m1985
Kim L, Hitaker M et al (2020) Hospitalization rates and characteristics of children aged<18 years hospitalized with laboratory-confirmed COVID-19 – COVID-NET, 14 States, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep 69(32):1081
doi: 10.15585/mmwr.mm6932e3
Hrusak O, Kalina T et al (2020) Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Eur J Cancer 132:11–16
doi: 10.1016/j.ejca.2020.03.021
Wolfs TFW, Attarbaschi A et al (2020) COVID-19 – impact on childhood haematology patients. Hemasphere 4(5):e465
doi: 10.1097/HS9.0000000000000465
Hamilton W (2020) Cancer diagnostic delay in the COVID-19 era: what happens next? Lancet Oncol 8:1000–1002
doi: 10.1016/S1470-2045(20)30391-0
Martin S, Ulrich C et al (2007) Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist 12:816–824
doi: 10.1634/theoncologist.12-7-816
Goyal S, Roscoe J et al (2004) Symptom interval in young people with bone cancer. Eur J Cancer 40:2280–2286
doi: 10.1016/j.ejca.2004.05.017
Brasme JF, Morfouace M et al (2012) Delays in diagnosis of paediatric cancers: a systematic review and comparison with expert testimony in lawsuits. Lancet Oncol 13(10):e445-459
doi: 10.1016/S1470-2045(12)70361-3
Offenbacher R, Knoll M, Loeb DM (2020) Delayed presentations of pediatric solid tumors at a tertiary care hospital in the Bronx due to COVID-19. Pediatr Blood Cancer 68(2):e28615. https://doi.org/10.1002/pbc.28615
doi: 10.1002/pbc.28615 pubmed: 32725878
Parasole R, Stellato P, Conter V et al (2020) Collateral effects of COVID-19 pandemic in pediatric hematooncology: fatalities caused by diagnostic delay. Pediatr Blood Cancer 67(8):e28482
doi: 10.1002/pbc.28482

Auteurs

Michal Dvori (M)

Department of Hematology-Oncology, Schneider Children's Medical Center of Israel, 14 Kaplan street, Petach Tikva, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Sarah Elitzur (S)

Department of Hematology-Oncology, Schneider Children's Medical Center of Israel, 14 Kaplan street, Petach Tikva, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Assaf Barg (A)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Pediatric Hematology, Oncology and BMT, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.

Shlomit Barzilai-Birenboim (S)

Department of Hematology-Oncology, Schneider Children's Medical Center of Israel, 14 Kaplan street, Petach Tikva, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Gil Gilad (G)

Department of Hematology-Oncology, Schneider Children's Medical Center of Israel, 14 Kaplan street, Petach Tikva, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Shirah Amar (S)

Department of Hematology-Oncology, Schneider Children's Medical Center of Israel, 14 Kaplan street, Petach Tikva, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Helen Toledano (H)

Department of Hematology-Oncology, Schneider Children's Medical Center of Israel, 14 Kaplan street, Petach Tikva, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Amos Toren (A)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Pediatric Hematology, Oncology and BMT, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.

Sigal Weinreb (S)

Department of Hematology-Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Gal Goldstein (G)

Department of Hematology-Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Adi Shapira (A)

Department of Pediatric Hematology-Oncology, Rambam Medical Center, and The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Shifra Ash (S)

Department of Pediatric Hematology-Oncology, Rambam Medical Center, and The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Shai Izraeli (S)

Department of Hematology-Oncology, Schneider Children's Medical Center of Israel, 14 Kaplan street, Petach Tikva, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Oded Gilad (O)

Department of Hematology-Oncology, Schneider Children's Medical Center of Israel, 14 Kaplan street, Petach Tikva, Israel. dkgsguss@gmail.com.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. dkgsguss@gmail.com.

Classifications MeSH